Objective: Clozapine-induced hypersalivation (CIH) is a significant side effect affecting about one-third of patients treated with clozapine. CIH can be stigmatizing, can affect quality of life, and can result in discontinuation of clozapine treatment. The purpose of this review is to provide an understanding of CIH, specifically, its pathophysiology, measurement, and the evidence for CIH treatment alternatives.
D espite the introduction of novel antipsychotic medications, clozapine remains the gold standard for treatment-refractory schizophrenia. 1, 2 Further, clozapine carries a minimal risk of extrapyramidal symptoms and prolactin elevation 1, 3 and is the antipsychotic of choice in patients suffering from tardive dyskinesia. 4 The risk of agranulocytosis has limited its widespread use, although recent data have shown that increased blood-monitoring protocols have lowered the risk of this hematologic complication. 5 However, tolerance and treatment adherence to clozapine are affected by more common side effects emerging early in the treatment course.
After sedation, hypersalivation, also referred to as sialorrhea or ptyalism, is the second most common side effect of clozapine. 6 The incidence of CIH is 31%, with symptoms occurring early in treatment and more often at night. 6 Sialorrhea can be profoundly stigmatizing and functionally disabling in certain patients, and it may increase discontinuation rates in this high-risk patient population. Sleep disturbance, social impairment, and embarrassment are potential sequelae of persistent hypersalivation. Further, chronic hypersalivation may result in swelling of salivary glands, parotitis, skin irritation, skin infection, or aspiration pneumonia. 7, 8 Therefore, understanding the possible mechanisms and treatment of hypersalivation is essential to improving patients' quality of life and compliance and the overall effectiveness of clozapine treatment.
Pathophysiology of CIH
To appreciate the effects of clozapine on salivation, a discussion of salivary pathophysiology is required. The parotid, submandibular, and sublingual salivary glands secrete 90% of the total 500 to 1500 mL of saliva produced daily. Fibres of the parasympathetic nervous system innervate salivary glands and induce saliva flow via vasodilation and increased blood flow. The sympathetic nervous system increases protein levels and plays a minor role in the salivary process. 9 Both muscarinic M 3 and M 4 receptors are expressed in salivary gland tissue and appear to exert opposing effects on one another, with M 3 blockade and M 4 stimulation both promoting hypersalivation. 10, 11 The extent to which other muscarinic receptors factor into this relation is unknown.
Clozapine has antagonistic properties at dopamine (D 1 to D 5 ), serotonin (5-HT 2 , 5-HT 4 ), histamine (H 1 ), adrenergic (alpha 1 and alpha 2 ), and muscarinic receptors (M 1 to M 3 , and M 5 ), although it acts as an agonist at the M 4 receptor. 11 Therefore, this combined muscarinic activity could explain the paradoxical effect of CIH despite its strong anticholinergic effects. Olanzapine, which also has direct M 4 -agonistic properties, is known to produce hypersalivation, whereas pirenzepine, an M 4 antagonist, alleviates sialorrhea. 12, 13 Data from saliva flow rate studies fail to provide an alternate explanation for CIH. 14, 15 Ben-Aryeh and colleagues compared saliva samples of 17 patients with schizophrenia with samples from 17 matched, unmedicated control subjects and found no difference in salivary composition or flow rates between the 2 groups. 14 This was confirmed in a second study that also showed no difference in salivary flow rates, using unstimulated saliva collection methods, and no correlation with clozapine dosage. 15 It should be noted that 15 patients in the former study complained of hypersalivation at night and that samples were taken during the day in both studies, suggesting, as an alternative hypothesis, a possible disruption in the circadian secretion of salivary flow.
In addition to its muscarinic activity, clozapine may exacerbate salivation through its alpha 2 antagonism. 16 However, data for mianserin, an antidepressant with a high affinity for the alpha 2 adrenoreceptor, failed to induce hypersalivation and produced the contradictory effect of dry mouth, casting doubt on the alpha 2 -adrenergic hypersalivation theory. 17 Such discrepancies have led others to consider deglutition disruption as an alternate mechanism of CIH. Some have purported that clozapine interrupts the normal coordination between the cortical and cranial nerve structures involved in swallowing. 18 Support for this theory is primarily derived from anecdotal reports of clozapine-induced dysfunction in peristalsis, sensations of nocturnal choking, and aspiration pneumonia. 7, 19, 20 Therefore, impairment in deglutition could contribute to saliva pooling and the subsequent development of CIH.
Assessment of CIH
Much of the literature on hypersalivation is plagued by difficulties in measuring saliva production, especially salivation occurring at night. 6 Praharaj and colleagues summarized objective and subjective methods for evaluating drooling severity and frequency; however, their review did not focus on methods specific to nocturnal CIH. 21 In addition to general patient self-reports, 22 rating scales such as the 5-point NHRS and the 15-minute observed drooling rating score. 23, 24 Objective measures have included measuring the diameter of the wet area on a pillow (visually or by tissue paper), 25, 26 unstimulated 5-minute saliva collection, 15 collection with a Salivette, 14 and saliva collection stimulated by citric acid. 14 Such quantitative measures often have practical limitations. For example, the use of wet tissue pads on pillows was only possible in a single study after a 1-week training period in an inpatient psychiatric setting. 25 Published studies investigating CIH are no exception to these methodological conundrums. Therefore, limitations in the assessment of hypersalivation should be considered in the trials described below when the study results are interpreted.
Management of CIH
Several studies have evaluated the treatment of CIH in patients with schizophrenia, although no single agent has demonstrated superior efficacy. Trials of local or systemic anticholinergic agents, antipsychotic agents, antidepressants, and alpha-adrenergic antagonists suggest they have a beneficial effect in treating CIH. The rest of our review focuses on the state of the current evidence in regard to treating CIH and attempts to summarize the available literature.
We searched MEDLINE from 1980 to June 2006 to identify all English-language, published CIH treatment studies and case reports in the literature. We used the following key words: hypersalivation, sialorrhea, clozapine, drooling, ptyalism, and treatment. The initial search yielded 34 articles, and we retrieved additional references from the bibliographies of the reviewed articles. We excluded studies that examined treatment approaches for conditions other than CIH or that failed to discuss specific pharmacologic interventions for treating CIH. We identified and incorporated into the review a total of 24 treatment studies. Table 1 provides a summary of the CIH treatment literature, excluding anecdotal reports and small case series (defined as n < 5 subjects). Although we allude to evidence from other study populations, we do not focus on these papers because of the distinct issues facing the treatment of drug-induced sialorrhea.
Anticholinergic Medication
The literature on the treatment of CIH has focused predominantly on anticholinergic agents, including selective and nonselective muscarinic receptor antagonists. Clozapine monotherapy has strong anticholinergic effects ranging from constipation to such serious complications as colon perforation. 27 Moreover, the combined use of clozapine and anticholinergic medications can increase such risks. Keeping this in mind, studies have explored the utility of M 4 receptor antagonists in the treatment of CIH. However, most of the evidence for anticholinergic treatment consists of open-label trials or case series, with only one randomized, placebocontrolled trial published to date 25 (see Table 1 ). Anticholinergic agents with systemic effects are contraindicated in patients with narrow-angle glaucoma, bladder obstruction, prostatic hypertrophy, and gastrointestinal motility disorders.
Benztropine
Although benztropine is a potential treatment option for hypersalivation, poor tolerability and adverse effects are a concern. 28 In a trial of 20 children with developmental disabilities, nearly 30% of benztropine-treated patients dropped out over the 5-week study period (10% owing to side effects alone). 29 Only one study has assessed the efficacy of benztropine therapy in patients suffering from CIH. 22 Reinstein and colleagues compared benztropine (1 mg twice daily), terazosin (2 mg at bedtime), terazosin and benztropine combination therapy, and no treatment in 60 patients over 12 weeks. Participants received a mean clozapine dosage of 325 mg daily; hypersalivation was measured by patient self-report and verified by staff, although the details of staff verification were not fully explained in the study. After 12 weeks, 0% of the patients receiving no treatment, 67.7% receiving benztropine, 93.3% receiving terazosin, and 100% receiving combination therapy experienced a resolution of CIH. Combination treatment also resulted in an increased speed of response over the course of the trial. Therefore, benztropine monotherapy failed to show superior efficacy in comparison with the combination, terazosin, and placebo treatment arms, although the lack of objective measures for saliva production limits these results.
Ipratropium Bromide
Trials using ipratropium bromide, an agent used typically for treating asthma, rhinorrhea, and perennial allergic rhinitis, have shown promising results in managing CIH. Unlike several other anticholinergic agents, ipratropium bromide has minimal systemic absorption, often undetectable plasma levels, and no central nervous system activity. 30 Tessier and Antonello 31 reported a case series of 10 patients who failed treatment of CIH with atropine eye drops. In this study, the authors switched patients to a 0.03% solution of ipratropium bromide nasal spray taken orally 1 to 2 times daily. All patients subjectively reported an improvement or resolution of nocturnal hypersalivation over the 6-month study period. Moreover, all patients tolerated ipratropium bromide and preferred its portability and uncomplicated administration.
Freudenriech and colleagues conducted a retrospective chart review of 9 stable outpatients suffering from CIH and treated with 2 sprays of 0.03% or 0.06% ipratropium bromide up to 3 times daily. 32 Of 9 patients, 7 reported at least a partial response to the nasal spray, although the effects typically In an open-label, uncontrolled study, Calderon and associates 33 attempted to formally evaluate the efficacy of ipratropium bromide therapy for CIH. Using the NHRS, they assessed hypersalivation in 10 patients suffering from schizophrenia, psychosis not otherwise specified, and psychotic disorder secondary to a temporal lobe infarct. Within 1 to 2 weeks, 6 of 10 patients reported at least a 1-point reduction in the NHRS. Two patients dropped out before the 6-month follow-up, 1 because of dry mouth secondary to ipratropium bromide and 1 because of nonresponse. At 6 months, 7 of 8 patients maintained the improvements noted in the first 2 weeks. The pre-and posttreatment values immediately and at 6 months achieved significance in this study. Although further research is required, these early results are promising, especially given the local effects of this anticholinergic agent.
Pirenzepine
As mentioned above, pirenzepine acts primarily through its selective M 1 and M 4 muscarinic receptor antagonistic activity and does not cross the blood-brain barrier. Typical dosages of pirenzepine used to treat CIH range from 25 to 100 mg daily, with mild diarrhea as a common adverse effect. 34 In Taiwan, the first randomized, double-blind, placebo-controlled cross-over study was conducted to evaluate the effects of pirenzepine on nocturnal CIH. 25 This alternating 8-week trial assessed salivation in 20 inpatients on a chronic ward by measuring the overnight diameter of saliva soaking the tissue paper placed over a pillow. Following a 1-week baseline period, patients were randomized to placebo or pirenzepine for 8 weeks, followed by a 4-week washout period and another 8 weeks of the alternate treatment. The mean decrease in nocturnal saliva-wetted surface diameter was 15.6%, SD 25%, and 6.2%, SD 35%, for pirenzepine and placebo, respectively, although these differences did not achieve statistical significance.
In an open-label study, Schneider and colleagues examined the effects of pirenzepine on clozapine levels and hypersalivation in 29 patients with schizophrenia. 13 Hypersalivation was measured clinically with the UKU side effect rating scale, and pirenzepine 50 mg daily was administered during the 3-day study. Clozapine treatment alone resulted in 69% of patients experiencing hypersalivation, compared with 35% of patients receiving additional pirenzepine therapy. Serum levels of clozapine and N-desmethylclozapine were increased in 14% of patients after pirenzepine was added. These results are limited by the short study duration and the lack of standardized saliva rating scales or objective measures.
Atropine
Atropine sulphate eye drops, administered intraorally, have resulted in amelioration of CIH in selected patients. [35] [36] [37] Dosages have ranged from 1 drop at bedtime to 2 drops twice daily, with no adverse effects noted in all 5 reported cases. Using atropine drops for CIH requires that patients rinse their mouths with the solution to maximize topical absorption and effectiveness, which can be a complicated procedure. Moreover, the therapeutic effects of atropine on CIH are often brief because of its short half-life, and its use may predispose patients to morning rebound hypersalivation. 31
Trihexyphenidyl
Trihexyphenidyl, a medication used in Parkinson disease and also used to treat extrapyramidal symptoms, is another treatment option for CIH. In an open-label study of 14 patients with chronic schizophrenia, Spivak and associates demonstrated a 44% mean reduction in NHRS scores after 12 days of treatment with trihexyphenidyl at a mean dosage of 10.7 mg daily, SD 2.7. 23
Hyoscine
Successful treatment of CIH with transdermal hyoscine (scopolamine) has been reported in the literature. Gaftanyuk and Trestman described successful treatment of CIH with transdermal scopolamine (1.5 mg) once every 72 hours in a female patient who was not successfully treated in prior trials of tolterodine, clonidine, and benztropine. 38 McKane and colleagues described the use of hyoscine patches (dosage 500 to 800 ìg daily) applied topically behind the ear every 72 hours in 4 patients suffering severe CIH; they reported a dramatic improvement in symptoms and quality of life. 39 Further, the authors noted that the hyoscine patch was effective in patients who had not previously responded to oral hyoscine. More rigorous research is required to make definitive conclusions on the efficacy of the hyoscine patch.
Amitriptyline
Tricyclic antidepressants were explored as a treatment for CIH because of their anticholinergic side effects. Copp and associates reported an amelioration of hypersalivation symptoms in 4 treatment-resistant patients with schizophrenia treated with amitriptyline, a tertiary amine tricyclic antidepressant, at a dosage of 75 to 100 mg daily. 40 The case series failed to include data on specific rating scales or objective measures for hypersalivation. Psychotic symptoms and tolerability did not worsen over the course of the patients' treatment.
Biperiden
In one case report, 41 biperiden, a centrally acting anticholinergic agent used in the treatment of parkinsonism, eliminated symptoms of CIH and hyperhidrosis when administered at a dosage of 6 mg daily.
Alpha 2 -Adrenergic Antagonists
Despite a paucity of literature regarding alpha 2 -adrenergic antagonists, some anecdotal and uncontrolled open data suggest their efficacy in treating CIH. Side effects such as hypotension, sedation, dizziness, urinary retention, constipation, or bradycardia may occur with these agents and limit tolerability in some patients. Nonetheless, the use of agents such as clonidine remains a viable option in cases of treatment-resistant CIH. Table 1 summarizes all CIH treatment trials involving alpha 2 -adrenergic antagonists, excluding small case series and case reports.
Clonidine
Proposed sympathetic effects on salivation have led to the investigation of clonidine therapy for CIH. Clonidine stimulates presynaptic alpha 2 autoreceptors, which results in a reduction of noradrenaline plasma levels. Early case series showed improvements in CIH in 2 of 4 patients receiving a clonidine patch (0.1 to 0.2 mg weekly), even though 1 patient developed tolerance to treatment. 42 In an uncontrolled open-label trial, Praharaj and colleagues evaluated the efficacy of oral clonidine in 12 stable outpatients with schizophrenia who were treated with clozapine (150 to 700 mg daily). 26 Treatment of CIH consisted of 0.05 mg daily of clonidine for the first 2 weeks, which was increased to 0.1 mg daily if no improvement was noted after this time. After 4 weeks, only 1 patient failed to achieve at least a 5-cm decrease in the patient-estimated diameter of the wet pillow's surface area, which was later verified by staff. The authors noted a clinically relevant reduction in wet-pillow diameter, and patients tolerated clonidine without significant side effects. Although the clonidine patch could potentially provide sustained drug levels to offset increased nocturnal hypersalivation, larger controlled trials are required to confirm its utility and safety in CIH. Worsening of postural hypotension can occur with the addition of clonidine to clozapine and should be carefully monitored.
Terazosin
As mentioned above, terazosin acts as an alpha 1 antagonist and has failed to show greater benefit in treating CIH than combined treatment with terazosin and benztropine. 22 Further, terazosin used in conjunction with clozapine could also increase the risk of hypotension during treatment.
Other Alpha 2 -Adrenergic Antagonists
Guanfacine, a medication for essential hypertension, has central sympathetic (alpha 2A receptor antagonist) activity and has been used to treat CIH. Webber and associates 43 described a case report of a woman who developed CIH while receiving 250 mg of clozapine and 1750 mg of valproic acid daily for schizoaffective disorder. Treatment with 1 mg of guanfacine daily was assessed by means of a 15-minute observed drooling rating score, and the authors noted a 3-point reduction in drooling score within 4 days of starting treatment. The study showed a sustained treatment response over a 1-month period. The best evidence for guanfacine treatment of hypersalivation is an RCT conducted in developmentally disabled children. 24 Lastly, Corrigan and colleagues used lofexidine to successfully treat a case of CIH; however, long-term treatment with this agent is limited by risks of depression and exacerbation of psychosis. 44
Other Treatments
Augmentation of clozapine with antipsychotic medications can increase the risk of clozapine-related side effects; however, studies have suggested that the antipsychotic class of substitute benzamide derivatives, such as amisulpride and sulpiride, may be effective in treating hypersalivation (see Table 1 ). Both antipsychotic agents have higher selective binding for the dopamine D 2 and D 3 receptors. Although these agents do not possess alpha 2 -adrenergic antagonist or anticholinergic activity, they may act in a manner similar to sulpiride-induced inhibition of gastric secretion via central nervous system dopamine blockade. 45 The addition of a second antipsychotic agent may also facilitate a reduction in clozapine dosage, which can reduce CIH symptoms. 46 Further, several studies have demonstrated improved antipsychotic efficacy and tolerability with amisulpride augmentation of clozapine therapy. [47] [48] [49] 
Sulpiride
Kreinin and colleagues conducted an uncontrolled trial (n = 18) to determine the efficacy of sulpiride augmentation in reducing CIH. 50 The addition of sulpiride (150 to 300 mg daily) was assessed with the NHRS over a 3-week period and resulted in a significant reduction in mean NHRS scores, with only 3 patients continuing to experience mild hypersalivation at the conclusion of the study.
Amisulpride
In a 7-week, randomized, double-blind, controlled cross-over study, 20 patients with schizophrenia and CIH were randomized to amisulpride (400 mg daily) or placebo. 51 Each 3-week treatment phase was separated by a 1-week washout period. The authors observed a significant reduction in NHRS scores in patients receiving amisulpride treatment (mean 1.79, SD 1.25) compared with placebo (mean 2.63, SD 1.33). A significant improvement appeared in the Negative Symptoms subscale of the PANSS, but no differences were noted in the CGI scale or in extrapyramidal symptoms.
Botulinum Toxin
Several RCTs involving BTX have shown promise in the treatment of sialorrhea secondary to Parkinson disease. [52] [53] [54] Injection of BTX into parotid glands is thought to reduce saliva production by inhibiting cholinergic autonomic parasympathetic and postganglionic sympathetic acetylcholine release in the salivary glands. As a result, BTX treatment has been investigated in patients with CIH. Kahl and associates reported a case of a male patient with schizophrenia and severe hypersalivation receiving clozapine 600 mg daily. 55 After not responding in a trial of atropine, the patient experienced a distinct reduction in CIH following bilateral parotid gland injection with BTX A (150 IU). Although the current level of evidence is limited to anecdotal reports, it is possible that future trials will yield similar results to those found in the patients with Parkinson disease suffering from sialorrhea. Despite these preliminary findings, the utility of BTX is limited by its invasive nature and potential for major complications, such as jaw dislocation. 56 However, certain patients with CIH may benefit from BTX treatment, particularly patients who have failed to respond to previous augmentation strategies or who have experienced significant adverse effects with prior hypersalivation treatment.
Conclusion
Despite clozapine's superior efficacy in cases of treatmentresistant schizophrenia, compliance and tolerability remain imperative to its success. Hypersalivation is among the most troublesome and common side effects affecting clozapine-treated patients. Although this review has focused on specific pharmacologic approaches for CIH, clinicians should first consider treatment approaches that are more benign to minimize the adverse effects resulting from polypharmacy. First-line nonpharmacologic strategies include placing a towel over a pillow to reduce soaking at night and chewing sugarless gum during the day to facilitate swallowing. 57 Anatomical defects such as septal deviation can contribute to CIH symptoms and can be corrected with surgery. 58 Other causes of hypersalivation, such as medications and neuromuscular disorders, should be considered when evaluating CIH symptoms. Although the relation between CIH and clozapine dosage remains unclear at this time, dose reduction can be considered in some cases on a trial basis, provided psychotic symptoms remain stabilized. 14, 22, 32 Although hypersalivation can significantly affect clozapine treatment, little literature exists regarding the treatment of CIH. As discussed in this review, published studies are limited to smaller RCTs and open-label studies. Most of the evidence has focused on anticholinergic agents such as pirenzepine, with inconclusive results. It should be noted that pirenzepine, lofexidine, sulpiride, and amisulpride are not available in Canada and the United States, which limits CIH treatment options. Larger trials are required to provide definitive guidelines and to evaluate the efficacy of therapies such as ipratropium bromide. Treatment recommendations should be tailored to each individual case and should consider the severity of hypersalivation symptoms and potential treatment benefits. The studies reviewed above can offer some useful treatment alternatives when initial CIH management strategies fail.
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